Impact of different PSMA PET-based eligibility criteria on outcome of [177Lu]Lu-PSMA radioligand therapy using [18F]rhPSMA-7/[18F]rhPSMA-7.3 (Flotufolastat) [0.03%]
不同PSMA PET纳入标准对[177Lu]Lu-PSMA放射配体治疗结局的影响（使用[18F]rhPSMA-7/[18F]rhPSMA-7.3(Flotufolastat)）
Sonia Grigorascu,Thomas Langbein,Isabel Rauscher et al.
Sonia Grigorascu et al.
Background: [177Lu]Lu-PSMA radioligand therapy (RLT) is key in treating metastatic castration-resistant prostate cancer (mCRPC). Various PSMA agents and eligibility criteria for [177Lu]Lu-PSMA RLT have been described. We ...
First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer [0.03%]
前列腺癌和乳腺癌患者中GRPR拮抗剂[68Ga]Ga-NOTA-Peg2-Rm26首次人体试验的放射性剂量学研究
Annie Bjäreback,Ulrika Estenberg,Antonios Tzortzakakis et al.
Annie Bjäreback et al.
Background: Gastrin-releasing peptide receptor (GRPR) is overexpressed in several malignant tumours, while its physiological expression in major organs, except for pancreas, is low. GRPR is therefore an interesting target...
Early timepoint 99mTc-DPD whole body scintigraphy and quantitative SPECT/CT imaging for diagnosis of cardiac ATTR amyloidosis [0.03%]
早期时相99mTc-DPD全身闪烁显像及定量SPECT/CT成像在心脏ATTR淀粉样变性诊断中的应用价值研究
Stephan Settelmeier,Lukas Kessler,Noah Hammersen et al.
Stephan Settelmeier et al.
Background: Cardiac transthyretin amyloidosis (ATTR-CM) is a progressive myocardial disease ultimately leading to heart failure. Standard diagnostic workup includes 99mTc-DPD scintigraphy performed after 2.5-3 h. The purp...
Incidental [68Ga]Ga-DOTATATE uptake in bone metastases of breast carcinoma in a patient with a secondary carcinoid tumor [0.03%]
乳腺癌骨转移偶然摄取[68Ga]Ga-DOTATATE一例(合并继发类癌)
Jan Kemle,Sabin G Pop,Alexander Sauter et al.
Jan Kemle et al.
Background: Lobular breast cancer often shows only low [18F]FDG uptake, limiting the sensitivity to detect metastases. Alternative tracers, targeting tumor activated fibroblasts or estrogen receptors, can offer higher acc...
Complementary roles of 68Ga-FAPI and 18 F-FDG PET/CT in evaluating IgG4-related disease: a systematic review and pooled analysis [0.03%]
~sup>68Ga-FAPI和~sup>18F-FDG PET/CT在IgG4相关性疾病评估中的互补作用：系统性回顾及汇总分析
Xue Cai,Qin Wang,Qingfan Hao et al.
Xue Cai et al.
Background: IgG4-related disease (IgG4-RD) lacks standardized imaging criteria. This study systematically reviewed head-to-head comparisons of 68Ga-FAPI and 18F-FDG PET/CT to clarify their complementary roles in diagnosin...
Experimental study of [68Ga]Ga-HER2-RGD, a dual-target molecular probe, for breast cancer PET/CT imaging [0.03%]
~(~(68)Ga)Ga-HER2-RGD双靶向分子探针乳腺癌显像的实验研究
Xiujuan Zhao,Meng Dai,Tianyue Li et al.
Xiujuan Zhao et al.
Background: Radiolabeled heterodimeric peptides have emerged as a highly promising targeting strategy for PET imaging due to their superior binding properties. The Human epidermal growth factor receptor 2 (HER2)- and Arg-...
Quantitative mid-treatment imaging biomarkers for response prediction after radiotherapy in head and neck cancer: a systematic review and meta-analysis [0.03%]
头颈部癌症放疗后的反应预测中期影像生物标志物的系统评价和meta分析
Yuvnik Trada,Mark T Lee,Michael G Jameson et al.
Yuvnik Trada et al.
Background: To systematically review and meta-analyse the prognostic value of quantitative mid-treatment imaging biomarkers for predicting locoregional tumour control in patients undergoing definitive radiotherapy for muc...
Head to head comparison of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT in the diagnosis and staging of pancreatic cancer: a prospective study [0.03%]
68镓-Ga-FAPI-04和18氟-FDG正电子发射断层扫描/X线计算机体层成像在胰腺癌诊断和分期中的比较：一项前瞻性研究
Ruoxi Yang,Yuhan Sun,Ran An et al.
Ruoxi Yang et al.
Background: [68Ga]Ga-FAPI-04 targets FAP overexpressed in pancreatic cancer microenvironment. This study compared diagnostic efficacy and clinical impact with [18F]FDG PET/CT in pancreatic cancer. ...
Mehmet Necmeddin Sutaşır,Banu Arslan,Mohamed Mukhtar Mohamed et al.
Mehmet Necmeddin Sutaşır et al.
Background: Nuclear medicine procedures are increasingly integrated into routine clinical practice worldwide, including in low- and middle-income settings. Although radiopharmaceuticals have a well-established safety prof...
GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer [0.03%]
来自骨转移雄激素耐药性前列腺癌患者多中心前瞻性研究的基因组-wide关联分析（针对223镭治疗）
Tokiyoshi Tanegashima,Masaki Shiota,Atsushi Doi et al.
Tokiyoshi Tanegashima et al.
Background: Radium-223 dichloride improves survival and delays symptomatic skeletal events in patients with bone-metastatic castration-resistant prostate cancer; however, therapeutic responses vary considerably among indi...